Posted by Michael Wonder on 16 Jun 2022
Subsidy for medicine for Duchenne muscular dystrophy expires
16 June 2022 - The TLV has decided that Translarna, which is subsidised for patients with Duchenne muscular dystrophy, will not be included in the high-cost protection after 30 June 2022.
The medicine has proven to have a worse effect than adopted temporarily in spring 2019.
